.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
UBS
Julphar
Moodys
Deloitte
Chubb
AstraZeneca
McKinsey
Teva
Healthtrust

Generated: June 24, 2017

DrugPatentWatch Database Preview

HICON Drug Profile

« Back to Dashboard

What is the patent landscape for Hicon, and when can generic versions of Hicon launch?

Hicon is a drug marketed by Jubilant Draximage and is included in one NDA.

The generic ingredient in HICON is sodium iodide i-131. There are one thousand three hundred and seventy-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the sodium iodide i-131 profile page.

Summary for Tradename: HICON

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:HICON at DailyMed

Pharmacology for Tradename: HICON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Jubilant Draximage
HICON
sodium iodide i-131
SOLUTION;ORAL021305-002Jan 24, 2003DISCNNoNo► Subscribe► Subscribe
Jubilant Draximage
HICON
sodium iodide i-131
SOLUTION;ORAL021305-007Dec 5, 2011RXYesYes► Subscribe► Subscribe
Jubilant Draximage
HICON
sodium iodide i-131
SOLUTION;ORAL021305-003Jan 24, 2003DISCNNoNo► Subscribe► Subscribe
Jubilant Draximage
HICON
sodium iodide i-131
SOLUTION;ORAL021305-005Apr 4, 2006DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Federal Trade Commission
Cipla
Covington
Harvard Business School
Moodys
McKinsey
Cerilliant
QuintilesIMS
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot